TrialBlood neoplasia2025

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.

Naveen Pemmaraju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.